Komodor Scales U.S. Operations with Key Sales and Engineering Leadership Appointments
Komodor has expanded its U.S. sales and technical leadership by appointing Kelly Freeman as VP of Sales (Central & West) and Ricardo Lupo as Global Head of Sales Engineering to support growing demand for Kubernetes management and cost automation.
Share
With over 20 years of experience leading sales teams in observability, cybersecurity and cloud, Kelly will head Komodor's go-to-market efforts in the U.S. Central and West. He joins Komodor from Spot.io (acquired by Flexera), where he led global sales for FinOps and cloud observability. Previously Kelly was VP of sales at RiskIQ and Applause, and served in senior sales leadership roles at New Relic, HP Software, VMware, and Tivoli (acquired by IBM).
'Kelly's experience helping customers modernize infrastructure and optimize cloud operations directly supports our mission to make Kubernetes easier for everyone,' said Jim Hunnewell, CRO at Komodor. 'His leadership will be critical as we grow our U.S. presence and scale our customer base.'
Ricardo Lupo joins Komodor as Global Head of Sales Engineering, overseeing technical pre-sales, customer support, and solution engineering across global operations. At Grafana Labs he advanced adoption of open-source monitoring solutions, and at Mezmo (formerly LogDNA), he helped transition the company into full-stack observability. He also played pivotal roles at Sysdig and Chef Software, as well as spearheading major initiatives while leading engineering teams at Credit Suisse and Merrill Lynch.
'Ricardo has a unique ability to bridge technical depth with customer success,' said Hunnewell. 'He'll play a pivotal role in helping customers adopt and scale Komodor's automation platform with confidence.'
About Komodor
Komodor reduces the cost and complexity of managing large-scale Kubernetes environments by automating day-to-day operations, as well as health and cost optimization. The Komodor Platform proactively identifies risks that can impact application availability, reliability and performance, while providing AI-assisted root-cause analysis, troubleshooting and automated remediation playbooks. Fortune 500 companies in a wide range of industries including financial services, retail and more, rely on Komodor to empower developers, reduce TicketOps, and harness the full power of Kubernetes to accelerate their business. The company has received $67M in funding from Accel, Felicis, NFX Capital, OldSlip Group, Pitango First, Tiger Global, and Vine Ventures. For more information visit https://komodor.com/, join the Komodor Kommunity, and follow us on LinkedIn and X.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 minutes ago
- Business Wire
Cybin Announces Results of Annual Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the ' Meeting '). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below: 1. Appointment of Auditor Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below: 2. Number of Directors The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below: 3. Election of Directors Each of the nominees for election as director listed in Cybin's management information circular dated July 14, 2025 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below: George Tziras did not stand for re-election as a director. The Company thanks Mr. Tziras for his past service. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Business Wire
9 minutes ago
- Business Wire
Capvidia brings MBD for Suppliers with browser-based 3D human-viewable models linked to QIF/STEP
CHICAGO--(BUSINESS WIRE)-- Capvidia, a global leader in Model-Based Definition (MBD) and Model-Based Enterprise (MBE) software, announced a major milestone for MBDVidia: 3D human-viewable HTML models synchronized with QIF and STEP AP242. The result is OEM MBD that suppliers can use anywhere with no CAD required. How it works: MBDVidia publishes standards-based QIF/STEP from native CAD (Creo, CATIA, SOLIDWORKS, Autodesk, etc.) and now generates a linked HTML viewable (and PDF). Any browser can open the interactive 3D model and PMI, giving procurement, manufacturing, quality, and the shop floor a shared, authoritative view in a user-friendly way. Why it matters for Suppliers: No CAD seats: Open interactive 3D + PMI in any modern browser. Faster RFQs: See features, GD&T, and tolerances in 3D to quote accurately. Fewer errors: Viewable is linked to QIF/STEP and native CAD—preserves intent. Bill of Characteristics click-through: Jump from each characteristic to the exact PMI on the model. Shop-floor friendly: Zoom, section, filter PMI; run on tablets or kiosks. Quality ready: Linked QIF speeds FAI/PPAP and audit-ready traceability. Clear changes: Model-to-characteristic traceability improves ECO handling. Start 2D → scale 3D: Use HTML as a low-friction on-ramp from PDFs. 'Capvidia is about simplifying collaboration between OEMs and suppliers,' said Tomasz Luniewski, CEO of Capvidia. 'By pairing standards-based QIF/STEP with an interactive browser view, we make MBD universally accessible so quoting, programming, and quality teams can move faster with fewer mistakes.' Learn more: MBDVidia at Get MBD ready: Request a demo at About Capvidia Capvidia is the global authority on MBD/MBE. We make the 3D model the single source of truth, auto-generating PMI and characteristics to eliminate manual ballooning and automate workflows from design through quality. Built on open standards (QIF, STEP AP242) and native CAD, our software delivers true interoperability across CAD, CAM, CMM, and PLM—without loss of intent. The result is a complete, auditable, traceable digital thread linking every requirement to real-world results across OEMs and suppliers. Trusted by leading aerospace, defense, medical-device, and industrial manufacturers, Capvidia helps teams move faster, prove conformance, and collaborate with confidence.
Business Wire
18 minutes ago
- Business Wire
Figma to Announce Second Quarter 2025 Financial Results on September 3, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Figma, Inc. (NYSE: FIG) today announced that its second quarter 2025 financial results will be released after the U.S. financial markets close on Wednesday, September 3, 2025. Figma will host a conference call to discuss its results and guidance at 2 p.m. PT / 5 p.m. ET the same day. Access to the live webcast of the call and related earnings materials are available through the Investor Relations page on Figma's website at Following the call, a replay and transcript of the webcast will be available at the same website. If you would like to submit a question to be answered on the call, please reach out to ir@ Disclosure Information Figma announces material information to the public through filings with the Securities and Exchange Commission, the Investor Relations page on its website ( its blog ( its newsroom ( press releases, public conference calls, public webcasts, its social media accounts on X, LinkedIn, Instagram, Bluesky, Threads, and TikTok as well as Dylan Field's X account (@zoink) and LinkedIn profile in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD. About Figma Figma is where teams come together to turn ideas into the world's best digital products and experiences. Founded in 2012, Figma has evolved from a design tool to a connected, AI-powered platform that helps teams go from idea to shipped product. Whether you're ideating, designing, building, or shipping, Figma makes the entire design and product development process more collaborative, efficient, and fun—while keeping everyone on the same page.
